Author

I. Busnadiego

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Microbiology· 4 Immunology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 4 Research Focus:drug response / drug discovery· 3 Research Focus:host-pathogen & immune response· 3 Organism:human· 3 Assay:bulk RNA-seq· 2 Approach:deep learning· 1 Research Focus:gene regulatory network inference· 1 Approach:genetic perturbation / CRISPR· 1

Frequent Co-Authors

B. G. Hale· 4 shared I. Glas· 2 shared M. O. Pohl· 2 shared S. Stertz· 2 shared A. Caflisch· 1 shared A. E. Firth· 1 shared A. Hunziker· 1 shared A. Trkola· 1 shared

Activity by Year

2020-2021 · peak 3/yr

Co-Author Collaboration Network

10 top collaborators · 23 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

4 shared papersMicrobiology

B. G. Hale

Mutual co-authors in cluster

Author profile →

5 papers

Recent·Most cited

Combined computational and cellular screening identifies synergistic inhibition of SARS-CoV-2 by lenvatinib and remdesivir

M. O. Pohl, I. Busnadiego, F. Marrafino, L. Wiedmer, A. Hunziker, S. Fernbach, I. Glas, E. V. Moroz-Omori, B. G. Hale, A. Caflisch, S. Stertz

This study combines computational screening and cellular assays to identify lenvatinib and remdesivir as synergistic inhibitors of SARS-CoV-2 replication in Vero-CCL81 cells.

bioRxiv · Mar 19, 2021Microbiology

Manipulation of the unfolded protein response: a pharmacological strategy against coronavirus infection

L. Echavarria-Consuegra, G. M. Cook, I. Busnadiego, C. Lefevre, S. Keep, K. Brown, N. Doyle, G. Dowgier, K. Franaszek, N. A. Moore, S. G. Siddell, E. Bickerton, B. G. Hale, A. E. Firth, I. Brierley, N. Irigoyen

This paper investigates the unfolded protein response (UPR) in coronavirus infection and shows that pharmacological inhibition of the UPR significantly reduces viral replication.

bioRxiv · Mar 19, 2021Microbiology

Genome-Wide CRISPR Screening Identifies BRD9 as a Druggable Component of Interferon-Stimulated Gene Expression and Antiviral Activity

J. Börold, D. Eletto, I. Busnadiego, N. K. Mair, E. Moritz, S. Schiefer, N. Schmidt, P. P. Petric, W. W.-L. Wong, M. Schwemmle, B. G. Hale

This study identifies BRD9 as a critical component of IFN signaling and antiviral activity through CRISPR screening, showing its druggability for targeting constitutive ISG expression.

bioRxiv · Feb 4, 2021Immunology

SARS-CoV-2 Variants Reveal Features Critical for Replication in Primary Human Cells

M. O. Pohl, I. Busnadiego, V. Kufner, I. Glas, U. Karakus, S. Schmutz, M. Zaheri, I. Abela, A. Trkola, M. Huber, S. Stertz, B. G. Hale

This study identifies SARS-CoV-2 variants with distinct replication abilities in human and non-human cells, highlighting cell-specific replication features.

bioRxiv · Oct 22, 2020Microbiology

Modelling the interaction between Infectious Bursal Disease Virus VP3 polypeptide and dsRNA: identification of key residues for ribonucleoprotein assembly and virus replication

I. Busnadiego, M. T. Martin, D. S. Ferrero, M. G. Millan de la Blanca, L. Broto, E. Diaz-Beneitez, D. Fuentes, D. Rodriguez, N. Verdaguer, L. Kremer, J. F. Rodriguez

This study identifies key residues in IBDV VP3 for dsRNA binding and virus replication by analyzing mutant versions and their effects on ribonucleoprotein assembly and host evasion.

bioRxiv · Aug 6, 2020 · PreprintMicrobiology